A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-012
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 01 Mar 2018 Results from the subset of patients with recurrent or metastatic head and neck squamous cell carcinoma (n=26) published in the Cancer Science
    • 15 Feb 2018 Planned End Date changed from 17 Jan 2018 to 17 Jan 2019.
    • 06 Jun 2017 Results evaluating tumor and immune cells using the combined positive score method in patient specimens for the gastric indication, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top